Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company that discovers and develops small molecule drug candidates targeting cancer. The company generates no product revenue, funding operations through equity and debt financing while advancing its pipeline toward regulatory approval. As of the 10-K filed March 26, 2026, Zentalis reported net cash used in operating activities of $125.2 million for the year ended December 31, 2025, down from $170.9 million in the year ended December 31, 2024. The lead candidate is azenosertib, a small molecule being evaluated in clinical trials, including in combination with other therapies. Zentalis has never declared or paid a cash dividend and does not anticipate doing so. Julie Eastland serves as President and Chief Executive Officer. The company has no credit facility or committed sources of capital and relies on capital markets to fund ongoing research and development.

Revenue model

Pre-revenue clinical-stage company. Operations are funded through equity issuances and potential future collaboration, licensing, or partnership arrangements. No product revenue has been reported in the excerpts from the 10-K filed March 26, 2026.

Products and services

Azenosertib, a small molecule drug candidate being evaluated in clinical trials for cancer indications, including in combination with other therapies. Additional pipeline candidates are referenced but not individually named in the available excerpts.

Customers and end markets

End market is oncology. Target prescribers are physicians treating cancer patients. No commercial products have been approved and no customer revenue is reported as of the 10-K filed March 26, 2026.

Value-chain role

Drug discoverer and clinical-stage developer. Zentalis conducts research, preclinical work, and clinical trials internally and through third-party contract organizations. Commercial sales infrastructure has not yet been built; the company is evaluating internal build-out versus third-party collaboration for future commercialization.

Geographic exposure

Incorporated and headquartered in the United States. Clinical trials reference FDA and ex-U.S. regulatory authorities, indicating some international trial activity, but no specific geographic revenue breakdown is provided in the available excerpts.

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: CHINOOK THERAPEUTICS, INC. Akero Therapeutics, Inc. Veracyte Inc Deciphera Pharmaceuticals, Inc. Kyntra Bio Inc Gossamer Bio Inc Kymera Therapeutics Inc Rhythm Pharmaceuticals Inc SpringWorks Therapeutics, Inc.